Results	O
of	O
an	O
International	B:C0033267
Postmarketing	I:C0033267
Surveillance	I:C0033267
Study	I:C0033267
of	O
pl-VEGF165	O
Safety	O
and	O
Efficacy	O
in	O
210	O
Patients	O
with	O
Peripheral	O
Arterial	I:C1704436
Disease	I:C1704436
.	O

Results	O
of	O
an	O
International	O
Postmarketing	I:C0033267
Surveillance	I:C0033267
Study	I:C0033267
of	O
pl-VEGF165	B:C1254351
Safety	O
and	O
Efficacy	O
in	O
210	O
Patients	O
with	O
Peripheral	O
Arterial	I:C1704436
Disease	I:C1704436
.	O

Results	O
of	O
an	O
International	O
Postmarketing	I:C0033267
Surveillance	I:C0033267
Study	I:C0033267
of	O
pl-VEGF165	O
Safety	O
and	O
Efficacy	O
in	O
210	O
Patients	O
with	O
Peripheral	B:C1704436
Arterial	I:C1704436
Disease	I:C1704436
.	O

The	O
effective	O
treatment	B:C0087111
of	O
chronic	O
lower	O
limb	I:C0023216
ischemia	O
is	O
one	O
of	O
the	O
most	O
challenging	O
issues	O
confronting	O
vascular	O
surgeons	I:C0586909
.	O

The	O
effective	O
treatment	O
of	O
chronic	O
lower	B:C0023216
limb	I:C0023216
ischemia	O
is	O
one	O
of	O
the	O
most	O
challenging	O
issues	O
confronting	O
vascular	O
surgeons	I:C0586909
.	O

The	O
effective	O
treatment	O
of	O
chronic	O
lower	O
limb	I:C0023216
ischemia	B:C0022116
is	O
one	O
of	O
the	O
most	O
challenging	O
issues	O
confronting	O
vascular	O
surgeons	I:C0586909
.	O

The	O
effective	O
treatment	O
of	O
chronic	O
lower	O
limb	I:C0023216
ischemia	O
is	O
one	O
of	O
the	O
most	O
challenging	O
issues	O
confronting	O
vascular	B:C0586909
surgeons	I:C0586909
.	O

Current	O
pharmacological	O
therapies	B:C0087111
play	O
an	O
auxiliary	O
role	O
and	O
cannot	O
prevent	O
disease	O
progression	I:C0242656
,	O
and	O
new	O
treatment	O
methods	I:C0087111
are	O
needed	O
.	O

Current	O
pharmacological	O
therapies	O
play	O
an	O
auxiliary	O
role	O
and	O
cannot	O
prevent	O
disease	B:C0242656
progression	I:C0242656
,	O
and	O
new	O
treatment	O
methods	I:C0087111
are	O
needed	O
.	O

Current	O
pharmacological	O
therapies	O
play	O
an	O
auxiliary	O
role	O
and	O
cannot	O
prevent	O
disease	O
progression	I:C0242656
,	O
and	O
new	O
treatment	B:C0087111
methods	I:C0087111
are	O
needed	O
.	O

pl	B:C1254351
-VEGF165	I:C1254351
,	O
a	O
gene	O
therapy	I:C0017296
drug	O
,	O
was	O
approved	O
in	O
Russia	O
for	O
the	O
treatment	O
of	O
atherosclerotic	O
peripheral	O
arterial	I:C1704436
disease	I:C1704436
(	O
peripheral	O
arterial	I:C1704436
disease	I:C1704436
)	O
after	O
clinical	O
studies	I:C0008972
in	O
2011	O
.	O

pl	O
-VEGF165	I:C1254351
,	O
a	O
gene	B:C0017296
therapy	I:C0017296
drug	O
,	O
was	O
approved	O
in	O
Russia	O
for	O
the	O
treatment	O
of	O
atherosclerotic	O
peripheral	O
arterial	I:C1704436
disease	I:C1704436
(	O
peripheral	O
arterial	I:C1704436
disease	I:C1704436
)	O
after	O
clinical	O
studies	I:C0008972
in	O
2011	O
.	O

pl	O
-VEGF165	I:C1254351
,	O
a	O
gene	O
therapy	I:C0017296
drug	B:C1254351
,	O
was	O
approved	O
in	O
Russia	O
for	O
the	O
treatment	O
of	O
atherosclerotic	O
peripheral	O
arterial	I:C1704436
disease	I:C1704436
(	O
peripheral	O
arterial	I:C1704436
disease	I:C1704436
)	O
after	O
clinical	O
studies	I:C0008972
in	O
2011	O
.	O

pl	O
-VEGF165	I:C1254351
,	O
a	O
gene	O
therapy	I:C0017296
drug	O
,	O
was	O
approved	O
in	O
Russia	B:C0035970
for	O
the	O
treatment	O
of	O
atherosclerotic	O
peripheral	O
arterial	I:C1704436
disease	I:C1704436
(	O
peripheral	O
arterial	I:C1704436
disease	I:C1704436
)	O
after	O
clinical	O
studies	I:C0008972
in	O
2011	O
.	O

pl	O
-VEGF165	I:C1254351
,	O
a	O
gene	O
therapy	I:C0017296
drug	O
,	O
was	O
approved	O
in	O
Russia	O
for	O
the	O
treatment	B:C0087111
of	O
atherosclerotic	O
peripheral	O
arterial	I:C1704436
disease	I:C1704436
(	O
peripheral	O
arterial	I:C1704436
disease	I:C1704436
)	O
after	O
clinical	O
studies	I:C0008972
in	O
2011	O
.	O

pl	O
-VEGF165	I:C1254351
,	O
a	O
gene	O
therapy	I:C0017296
drug	O
,	O
was	O
approved	O
in	O
Russia	O
for	O
the	O
treatment	O
of	O
atherosclerotic	O
peripheral	B:C1704436
arterial	I:C1704436
disease	I:C1704436
(	O
peripheral	O
arterial	I:C1704436
disease	I:C1704436
)	O
after	O
clinical	O
studies	I:C0008972
in	O
2011	O
.	O

pl	O
-VEGF165	I:C1254351
,	O
a	O
gene	O
therapy	I:C0017296
drug	O
,	O
was	O
approved	O
in	O
Russia	O
for	O
the	O
treatment	O
of	O
atherosclerotic	O
peripheral	O
arterial	I:C1704436
disease	I:C1704436
(	O
peripheral	B:C1704436
arterial	I:C1704436
disease	I:C1704436
)	O
after	O
clinical	O
studies	I:C0008972
in	O
2011	O
.	O

pl	O
-VEGF165	I:C1254351
,	O
a	O
gene	O
therapy	I:C0017296
drug	O
,	O
was	O
approved	O
in	O
Russia	O
for	O
the	O
treatment	O
of	O
atherosclerotic	O
peripheral	O
arterial	I:C1704436
disease	I:C1704436
(	O
peripheral	O
arterial	I:C1704436
disease	I:C1704436
)	O
after	O
clinical	B:C0008972
studies	I:C0008972
in	O
2011	O
.	O

The	O
study	B:C2603343
drug	O
is	O
an	O
original	O
gene	O
construction	I:C0012931
in	O
which	O
pl	O
-	I:C1254351
VEGF165	I:C1254351
1.2	O
mg	O
is	O
the	O
active	O
substance	I:C0574031
.	O

The	O
study	O
drug	B:C1254351
is	O
an	O
original	O
gene	O
construction	I:C0012931
in	O
which	O
pl	O
-	I:C1254351
VEGF165	I:C1254351
1.2	O
mg	O
is	O
the	O
active	O
substance	I:C0574031
.	O

The	O
study	O
drug	O
is	O
an	O
original	O
gene	B:C0012931
construction	I:C0012931
in	O
which	O
pl	O
-	I:C1254351
VEGF165	I:C1254351
1.2	O
mg	O
is	O
the	O
active	O
substance	I:C0574031
.	O

The	O
study	O
drug	O
is	O
an	O
original	O
gene	O
construction	I:C0012931
in	O
which	O
pl	B:C1254351
-	I:C1254351
VEGF165	I:C1254351
1.2	O
mg	O
is	O
the	O
active	O
substance	I:C0574031
.	O

The	O
study	O
drug	O
is	O
an	O
original	O
gene	O
construction	I:C0012931
in	O
which	O
pl	O
-	I:C1254351
VEGF165	I:C1254351
1.2	O
mg	O
is	O
the	O
active	B:C0574031
substance	I:C0574031
.	O

This	O
postmarketing	B:C0033267
surveillance	I:C0033267
study	I:C0033267
was	O
undertaken	O
to	O
evaluate	O
the	O
safety	O
(	O
identification	O
of	O
uncommon	O
side	O
effects	I:C0879626
)	O
and	O
efficacy	O
of	O
gene	O
therapy	I:C0017296
in	O
patients	O
in	O
routine	O
clinical	O
practice	O
.	O

This	O
postmarketing	O
surveillance	I:C0033267
study	I:C0033267
was	O
undertaken	O
to	O
evaluate	O
the	O
safety	O
(	O
identification	O
of	O
uncommon	O
side	B:C0879626
effects	I:C0879626
)	O
and	O
efficacy	O
of	O
gene	O
therapy	I:C0017296
in	O
patients	O
in	O
routine	O
clinical	O
practice	O
.	O

This	O
postmarketing	O
surveillance	I:C0033267
study	I:C0033267
was	O
undertaken	O
to	O
evaluate	O
the	O
safety	O
(	O
identification	O
of	O
uncommon	O
side	O
effects	I:C0879626
)	O
and	O
efficacy	O
of	O
gene	B:C0017296
therapy	I:C0017296
in	O
patients	O
in	O
routine	O
clinical	O
practice	O
.	O

In	O
total	O
,	O
210	O
patients	O
with	O
stage	O
II	O
-	O
III	O
chronic	O
limb	B:C0015385
ischemia	O
(	O
according	O
to	O
the	O
Fontaine	O
classification	I:C0282574
modified	O
by	O
AV	O
Pokrovsky	O
)	O
in	O
33	O
healthcare	O
facilities	I:C0018704
in	O
Russia	O
and	O
the	O
Ukraine	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

In	O
total	O
,	O
210	O
patients	O
with	O
stage	O
II	O
-	O
III	O
chronic	O
limb	O
ischemia	B:C0022116
(	O
according	O
to	O
the	O
Fontaine	O
classification	I:C0282574
modified	O
by	O
AV	O
Pokrovsky	O
)	O
in	O
33	O
healthcare	O
facilities	I:C0018704
in	O
Russia	O
and	O
the	O
Ukraine	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

In	O
total	O
,	O
210	O
patients	O
with	O
stage	O
II	O
-	O
III	O
chronic	O
limb	O
ischemia	O
(	O
according	O
to	O
the	O
Fontaine	B:C0282574
classification	I:C0282574
modified	O
by	O
AV	O
Pokrovsky	O
)	O
in	O
33	O
healthcare	O
facilities	I:C0018704
in	O
Russia	O
and	O
the	O
Ukraine	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

In	O
total	O
,	O
210	O
patients	O
with	O
stage	O
II	O
-	O
III	O
chronic	O
limb	O
ischemia	O
(	O
according	O
to	O
the	O
Fontaine	O
classification	I:C0282574
modified	O
by	O
AV	O
Pokrovsky	O
)	O
in	O
33	O
healthcare	B:C0018704
facilities	I:C0018704
in	O
Russia	O
and	O
the	O
Ukraine	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

In	O
total	O
,	O
210	O
patients	O
with	O
stage	O
II	O
-	O
III	O
chronic	O
limb	O
ischemia	O
(	O
according	O
to	O
the	O
Fontaine	O
classification	I:C0282574
modified	O
by	O
AV	O
Pokrovsky	O
)	O
in	O
33	O
healthcare	O
facilities	I:C0018704
in	O
Russia	B:C0035970
and	O
the	O
Ukraine	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

In	O
total	O
,	O
210	O
patients	O
with	O
stage	O
II	O
-	O
III	O
chronic	O
limb	O
ischemia	O
(	O
according	O
to	O
the	O
Fontaine	O
classification	I:C0282574
modified	O
by	O
AV	O
Pokrovsky	O
)	O
in	O
33	O
healthcare	O
facilities	I:C0018704
in	O
Russia	O
and	O
the	O
Ukraine	B:C0041580
were	O
enrolled	O
in	O
the	O
study	O
.	O

In	O
total	O
,	O
210	O
patients	O
with	O
stage	O
II	O
-	O
III	O
chronic	O
limb	O
ischemia	O
(	O
according	O
to	O
the	O
Fontaine	O
classification	I:C0282574
modified	O
by	O
AV	O
Pokrovsky	O
)	O
in	O
33	O
healthcare	O
facilities	I:C0018704
in	O
Russia	O
and	O
the	O
Ukraine	O
were	O
enrolled	O
in	O
the	O
study	B:C2603343
.	O

The	O
control	O
group	O
(	O
n	O
=	O
60	O
)	O
received	O
conservative	B:C0459914
therapy	I:C0459914
without	O
prostaglandins	O
and	O
prostacyclins	O
,	O
and	O
the	O
treatment	O
group	I:C1257890
(	O
n	O
=	O
150	O
)	O
received	O
treatment	O
with	O
pl	O
-	I:C1254351
VEGF165	I:C1254351
as	O
two	O
intramuscular	O
injections	O
for	O
a	O
total	O
dose	O
of	O
2.4	O
mg	O
.	O

The	O
control	O
group	O
(	O
n	O
=	O
60	O
)	O
received	O
conservative	O
therapy	I:C0459914
without	O
prostaglandins	B:C0033554
and	O
prostacyclins	O
,	O
and	O
the	O
treatment	O
group	I:C1257890
(	O
n	O
=	O
150	O
)	O
received	O
treatment	O
with	O
pl	O
-	I:C1254351
VEGF165	I:C1254351
as	O
two	O
intramuscular	O
injections	O
for	O
a	O
total	O
dose	O
of	O
2.4	O
mg	O
.	O

The	O
control	O
group	O
(	O
n	O
=	O
60	O
)	O
received	O
conservative	O
therapy	I:C0459914
without	O
prostaglandins	O
and	O
prostacyclins	B:C0205911
,	O
and	O
the	O
treatment	O
group	I:C1257890
(	O
n	O
=	O
150	O
)	O
received	O
treatment	O
with	O
pl	O
-	I:C1254351
VEGF165	I:C1254351
as	O
two	O
intramuscular	O
injections	O
for	O
a	O
total	O
dose	O
of	O
2.4	O
mg	O
.	O

The	O
control	O
group	O
(	O
n	O
=	O
60	O
)	O
received	O
conservative	O
therapy	I:C0459914
without	O
prostaglandins	O
and	O
prostacyclins	O
,	O
and	O
the	O
treatment	B:C1257890
group	I:C1257890
(	O
n	O
=	O
150	O
)	O
received	O
treatment	O
with	O
pl	O
-	I:C1254351
VEGF165	I:C1254351
as	O
two	O
intramuscular	O
injections	O
for	O
a	O
total	O
dose	O
of	O
2.4	O
mg	O
.	O

The	O
control	O
group	O
(	O
n	O
=	O
60	O
)	O
received	O
conservative	O
therapy	I:C0459914
without	O
prostaglandins	O
and	O
prostacyclins	O
,	O
and	O
the	O
treatment	O
group	I:C1257890
(	O
n	O
=	O
150	O
)	O
received	O
treatment	B:C0087111
with	O
pl	O
-	I:C1254351
VEGF165	I:C1254351
as	O
two	O
intramuscular	O
injections	O
for	O
a	O
total	O
dose	O
of	O
2.4	O
mg	O
.	O

The	O
control	O
group	O
(	O
n	O
=	O
60	O
)	O
received	O
conservative	O
therapy	I:C0459914
without	O
prostaglandins	O
and	O
prostacyclins	O
,	O
and	O
the	O
treatment	O
group	I:C1257890
(	O
n	O
=	O
150	O
)	O
received	O
treatment	O
with	O
pl	B:C1254351
-	I:C1254351
VEGF165	I:C1254351
as	O
two	O
intramuscular	O
injections	O
for	O
a	O
total	O
dose	O
of	O
2.4	O
mg	O
.	O

Pain	B:C0243095
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
(	O
Pain	O
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
)	O
(	O
the	O
primary	O
efficacy	O
criterion	O
for	O
Fontaine	O
stages	O
II	O
-	O
III	O
)	O
,	O
blood	O
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
(	O
blood	O
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
)	O
,	O
and	O
ankle	O
-	I:C1328319
brachial	I:C1328319
index	I:C1328319
(	O
ankle	O
-	I:C1328319
brachial	I:C1328319
index	I:C1328319
)	O
were	O
monitored	O
for	O
6	O
months	O
.	O

Pain	O
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
(	O
Pain	B:C0243095
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
)	O
(	O
the	O
primary	O
efficacy	O
criterion	O
for	O
Fontaine	O
stages	O
II	O
-	O
III	O
)	O
,	O
blood	O
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
(	O
blood	O
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
)	O
,	O
and	O
ankle	O
-	I:C1328319
brachial	I:C1328319
index	I:C1328319
(	O
ankle	O
-	I:C1328319
brachial	I:C1328319
index	I:C1328319
)	O
were	O
monitored	O
for	O
6	O
months	O
.	O

Pain	O
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
(	O
Pain	O
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
)	O
(	O
the	O
primary	O
efficacy	O
criterion	O
for	O
Fontaine	B:C0282574
stages	O
II	O
-	O
III	O
)	O
,	O
blood	O
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
(	O
blood	O
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
)	O
,	O
and	O
ankle	O
-	I:C1328319
brachial	I:C1328319
index	I:C1328319
(	O
ankle	O
-	I:C1328319
brachial	I:C1328319
index	I:C1328319
)	O
were	O
monitored	O
for	O
6	O
months	O
.	O

Pain	O
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
(	O
Pain	O
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
)	O
(	O
the	O
primary	O
efficacy	O
criterion	O
for	O
Fontaine	O
stages	O
II	O
-	O
III	O
)	O
,	O
blood	B:C0243095
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
(	O
blood	O
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
)	O
,	O
and	O
ankle	O
-	I:C1328319
brachial	I:C1328319
index	I:C1328319
(	O
ankle	O
-	I:C1328319
brachial	I:C1328319
index	I:C1328319
)	O
were	O
monitored	O
for	O
6	O
months	O
.	O

Pain	O
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
(	O
Pain	O
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
)	O
(	O
the	O
primary	O
efficacy	O
criterion	O
for	O
Fontaine	O
stages	O
II	O
-	O
III	O
)	O
,	O
blood	O
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
(	O
blood	B:C0243095
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
)	O
,	O
and	O
ankle	O
-	I:C1328319
brachial	I:C1328319
index	I:C1328319
(	O
ankle	O
-	I:C1328319
brachial	I:C1328319
index	I:C1328319
)	O
were	O
monitored	O
for	O
6	O
months	O
.	O

Pain	O
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
(	O
Pain	O
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
)	O
(	O
the	O
primary	O
efficacy	O
criterion	O
for	O
Fontaine	O
stages	O
II	O
-	O
III	O
)	O
,	O
blood	O
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
(	O
blood	O
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
)	O
,	O
and	O
ankle	B:C1328319
-	I:C1328319
brachial	I:C1328319
index	I:C1328319
(	O
ankle	O
-	I:C1328319
brachial	I:C1328319
index	I:C1328319
)	O
were	O
monitored	O
for	O
6	O
months	O
.	O

Pain	O
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
(	O
Pain	O
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
)	O
(	O
the	O
primary	O
efficacy	O
criterion	O
for	O
Fontaine	O
stages	O
II	O
-	O
III	O
)	O
,	O
blood	O
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
(	O
blood	O
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
)	O
,	O
and	O
ankle	O
-	I:C1328319
brachial	I:C1328319
index	I:C1328319
(	O
ankle	B:C1328319
-	I:C1328319
brachial	I:C1328319
index	I:C1328319
)	O
were	O
monitored	O
for	O
6	O
months	O
.	O

The	O
safety	O
of	O
pl	B:C1254351
-VEGF165	I:C1254351
gene	O
transfer	I:C1517499
in	O
terms	O
of	O
the	O
trial	O
protocol	I:C4255259
was	O
initially	O
evaluated	O
6	O
months	O
after	O
the	O
start	O
of	O
the	O
study	O
;	O
adverse	O
events	I:C0877248
(	O
adverse	O
events	I:C0877248
)	O
and	O
serious	O
adverse	I:C0877248
events	I:C0877248
(	O
serious	O
adverse	I:C0877248
events	I:C0877248
)	O
were	O
recorded	O
during	O
both	O
routine	O
visits	O
and	O
unscheduled	O
requests	O
for	O
medical	O
care	O
.	O

The	O
safety	O
of	O
pl	O
-VEGF165	I:C1254351
gene	B:C1517499
transfer	I:C1517499
in	O
terms	O
of	O
the	O
trial	O
protocol	I:C4255259
was	O
initially	O
evaluated	O
6	O
months	O
after	O
the	O
start	O
of	O
the	O
study	O
;	O
adverse	O
events	I:C0877248
(	O
adverse	O
events	I:C0877248
)	O
and	O
serious	O
adverse	I:C0877248
events	I:C0877248
(	O
serious	O
adverse	I:C0877248
events	I:C0877248
)	O
were	O
recorded	O
during	O
both	O
routine	O
visits	O
and	O
unscheduled	O
requests	O
for	O
medical	O
care	O
.	O

The	O
safety	O
of	O
pl	O
-VEGF165	I:C1254351
gene	O
transfer	I:C1517499
in	O
terms	O
of	O
the	O
trial	B:C4255259
protocol	I:C4255259
was	O
initially	O
evaluated	O
6	O
months	O
after	O
the	O
start	O
of	O
the	O
study	O
;	O
adverse	O
events	I:C0877248
(	O
adverse	O
events	I:C0877248
)	O
and	O
serious	O
adverse	I:C0877248
events	I:C0877248
(	O
serious	O
adverse	I:C0877248
events	I:C0877248
)	O
were	O
recorded	O
during	O
both	O
routine	O
visits	O
and	O
unscheduled	O
requests	O
for	O
medical	O
care	O
.	O

The	O
safety	O
of	O
pl	O
-VEGF165	I:C1254351
gene	O
transfer	I:C1517499
in	O
terms	O
of	O
the	O
trial	O
protocol	I:C4255259
was	O
initially	O
evaluated	O
6	O
months	O
after	O
the	O
start	O
of	O
the	O
study	O
;	O
adverse	B:C0877248
events	I:C0877248
(	O
adverse	O
events	I:C0877248
)	O
and	O
serious	O
adverse	I:C0877248
events	I:C0877248
(	O
serious	O
adverse	I:C0877248
events	I:C0877248
)	O
were	O
recorded	O
during	O
both	O
routine	O
visits	O
and	O
unscheduled	O
requests	O
for	O
medical	O
care	O
.	O

The	O
safety	O
of	O
pl	O
-VEGF165	I:C1254351
gene	O
transfer	I:C1517499
in	O
terms	O
of	O
the	O
trial	O
protocol	I:C4255259
was	O
initially	O
evaluated	O
6	O
months	O
after	O
the	O
start	O
of	O
the	O
study	O
;	O
adverse	O
events	I:C0877248
(	O
adverse	B:C0877248
events	I:C0877248
)	O
and	O
serious	O
adverse	I:C0877248
events	I:C0877248
(	O
serious	O
adverse	I:C0877248
events	I:C0877248
)	O
were	O
recorded	O
during	O
both	O
routine	O
visits	O
and	O
unscheduled	O
requests	O
for	O
medical	O
care	O
.	O

The	O
safety	O
of	O
pl	O
-VEGF165	I:C1254351
gene	O
transfer	I:C1517499
in	O
terms	O
of	O
the	O
trial	O
protocol	I:C4255259
was	O
initially	O
evaluated	O
6	O
months	O
after	O
the	O
start	O
of	O
the	O
study	O
;	O
adverse	O
events	I:C0877248
(	O
adverse	O
events	I:C0877248
)	O
and	O
serious	B:C0877248
adverse	I:C0877248
events	I:C0877248
(	O
serious	O
adverse	I:C0877248
events	I:C0877248
)	O
were	O
recorded	O
during	O
both	O
routine	O
visits	O
and	O
unscheduled	O
requests	O
for	O
medical	O
care	O
.	O

The	O
safety	O
of	O
pl	O
-VEGF165	I:C1254351
gene	O
transfer	I:C1517499
in	O
terms	O
of	O
the	O
trial	O
protocol	I:C4255259
was	O
initially	O
evaluated	O
6	O
months	O
after	O
the	O
start	O
of	O
the	O
study	O
;	O
adverse	O
events	I:C0877248
(	O
adverse	O
events	I:C0877248
)	O
and	O
serious	O
adverse	I:C0877248
events	I:C0877248
(	O
serious	B:C0877248
adverse	I:C0877248
events	I:C0877248
)	O
were	O
recorded	O
during	O
both	O
routine	O
visits	O
and	O
unscheduled	O
requests	O
for	O
medical	O
care	O
.	O

The	O
safety	O
of	O
pl	O
-VEGF165	I:C1254351
gene	O
transfer	I:C1517499
in	O
terms	O
of	O
the	O
trial	O
protocol	I:C4255259
was	O
initially	O
evaluated	O
6	O
months	O
after	O
the	O
start	O
of	O
the	O
study	O
;	O
adverse	O
events	I:C0877248
(	O
adverse	O
events	I:C0877248
)	O
and	O
serious	O
adverse	I:C0877248
events	I:C0877248
(	O
serious	O
adverse	I:C0877248
events	I:C0877248
)	O
were	O
recorded	O
during	O
both	O
routine	O
visits	B:C0008952
and	O
unscheduled	O
requests	O
for	O
medical	O
care	O
.	O

Overall	O
,	O
Pain	B:C0243095
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
increased	O
by	O
177	O
%	O
,	O
from	O
100.3	O
±	O
6.9	O
to	O
277.1	O
±	O
16.2	O
m	O
(	O
p	O
=	O
0.0001	O
)	O
,	O
in	O
the	O
treatment	O
group	I:C1257890
,	O
whereas	O
the	O
mean	O
value	O
was	O
unchanged	O
in	O
the	O
control	O
group	O
(	O
p	O
=	O
0.218	O
)	O
.	O

Overall	O
,	O
Pain	O
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
increased	O
by	O
177	O
%	O
,	O
from	O
100.3	O
±	O
6.9	O
to	O
277.1	O
±	O
16.2	O
m	O
(	O
p	O
=	O
0.0001	O
)	O
,	O
in	O
the	O
treatment	B:C1257890
group	I:C1257890
,	O
whereas	O
the	O
mean	O
value	O
was	O
unchanged	O
in	O
the	O
control	O
group	O
(	O
p	O
=	O
0.218	O
)	O
.	O

Both	O
blood	B:C0243095
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
and	O
ABI	O
values	I:C1328319
increased	O
by	O
24	O
%	O
(	O
p	O
=	O
0.0001	O
)	O
in	O
the	O
treatment	O
group	I:C1257890
but	O
decreased	O
in	O
the	O
control	O
group	O
.	O

Both	O
blood	O
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
and	O
ABI	B:C1328319
values	I:C1328319
increased	O
by	O
24	O
%	O
(	O
p	O
=	O
0.0001	O
)	O
in	O
the	O
treatment	O
group	I:C1257890
but	O
decreased	O
in	O
the	O
control	O
group	O
.	O

Both	O
blood	O
flow	I:C0243095
linear	I:C0243095
velocity	I:C0243095
and	O
ABI	O
values	I:C1328319
increased	O
by	O
24	O
%	O
(	O
p	O
=	O
0.0001	O
)	O
in	O
the	O
treatment	B:C1257890
group	I:C1257890
but	O
decreased	O
in	O
the	O
control	O
group	O
.	O

The	O
greatest	O
therapeutic	B:C1527144
effect	I:C1527144
was	O
observed	O
for	O
stage	O
III	O
disease	O
:	O
Pain	O
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
increased	O
by	O
683	O
%	O
(	O
p	O
=	O
0.0001	O
)	O
.	O

The	O
greatest	O
therapeutic	O
effect	I:C1527144
was	O
observed	O
for	O
stage	O
III	O
disease	B:C0012634
:	O
Pain	O
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
increased	O
by	O
683	O
%	O
(	O
p	O
=	O
0.0001	O
)	O
.	O

The	O
greatest	O
therapeutic	O
effect	I:C1527144
was	O
observed	O
for	O
stage	O
III	O
disease	O
:	O
Pain	B:C0243095
-	I:C0243095
free	I:C0243095
walking	I:C0243095
distance	I:C0243095
increased	O
by	O
683	O
%	O
(	O
p	O
=	O
0.0001	O
)	O
.	O

No	B:C1513916
angiogenic	O
therapy	I:C0087111
-	O
related	O
adverse	O
events	I:C0877248
or	O
side	O
effects	I:C0879626
were	O
recorded	O
,	O
and	O
target	O
limb	O
salvage	I:C0949591
was	O
96	O
and	O
97	O
%	O
in	O
the	O
treatment	O
and	O
control	O
groups	O
,	O
respectively	O
.	O

No	O
angiogenic	B:C0087111
therapy	I:C0087111
-	O
related	O
adverse	O
events	I:C0877248
or	O
side	O
effects	I:C0879626
were	O
recorded	O
,	O
and	O
target	O
limb	O
salvage	I:C0949591
was	O
96	O
and	O
97	O
%	O
in	O
the	O
treatment	O
and	O
control	O
groups	O
,	O
respectively	O
.	O

No	O
angiogenic	O
therapy	I:C0087111
-	O
related	O
adverse	B:C0877248
events	I:C0877248
or	O
side	O
effects	I:C0879626
were	O
recorded	O
,	O
and	O
target	O
limb	O
salvage	I:C0949591
was	O
96	O
and	O
97	O
%	O
in	O
the	O
treatment	O
and	O
control	O
groups	O
,	O
respectively	O
.	O

No	O
angiogenic	O
therapy	I:C0087111
-	O
related	O
adverse	O
events	I:C0877248
or	O
side	B:C0879626
effects	I:C0879626
were	O
recorded	O
,	O
and	O
target	O
limb	O
salvage	I:C0949591
was	O
96	O
and	O
97	O
%	O
in	O
the	O
treatment	O
and	O
control	O
groups	O
,	O
respectively	O
.	O

No	O
angiogenic	O
therapy	I:C0087111
-	O
related	O
adverse	O
events	I:C0877248
or	O
side	O
effects	I:C0879626
were	O
recorded	O
,	O
and	O
target	O
limb	B:C0949591
salvage	I:C0949591
was	O
96	O
and	O
97	O
%	O
in	O
the	O
treatment	O
and	O
control	O
groups	O
,	O
respectively	O
.	O

No	O
angiogenic	O
therapy	I:C0087111
-	O
related	O
adverse	O
events	I:C0877248
or	O
side	O
effects	I:C0879626
were	O
recorded	O
,	O
and	O
target	O
limb	O
salvage	I:C0949591
was	O
96	O
and	O
97	O
%	O
in	O
the	O
treatment	B:C1257890
and	O
control	O
groups	O
,	O
respectively	O
.	O

The	O
results	O
obtained	O
in	O
this	O
study	B:C2603343
are	O
not	O
significantly	O
different	O
from	O
those	O
observed	O
in	O
the	O
phase	O
IIb	I:C1706096
/	O
III	O
registration	O
clinical	O
study	I:C0008972
completed	O
in	O
2011	O
.	O

The	O
results	O
obtained	O
in	O
this	O
study	O
are	O
not	O
significantly	O
different	O
from	O
those	O
observed	O
in	O
the	O
phase	B:C1706096
IIb	I:C1706096
/	O
III	O
registration	O
clinical	O
study	I:C0008972
completed	O
in	O
2011	O
.	O

The	O
results	O
obtained	O
in	O
this	O
study	O
are	O
not	O
significantly	O
different	O
from	O
those	O
observed	O
in	O
the	O
phase	O
IIb	I:C1706096
/	O
III	B:C0282461
registration	O
clinical	O
study	I:C0008972
completed	O
in	O
2011	O
.	O

The	O
results	O
obtained	O
in	O
this	O
study	O
are	O
not	O
significantly	O
different	O
from	O
those	O
observed	O
in	O
the	O
phase	O
IIb	I:C1706096
/	O
III	O
registration	O
clinical	B:C0008972
study	I:C0008972
completed	O
in	O
2011	O
.	O

pl	B:C1254351
-VEGF165	I:C1254351
intramuscular	O
gene	O
transfer	I:C1517499
is	O
an	O
effective	O
treatment	O
for	O
moderate	O
to	O
severe	O
claudication	O
due	O
to	O
chronic	O
lower	O
limb	I:C0023216
ischemia	O
in	O
routine	O
clinical	O
practice	O
.	O

pl	O
-VEGF165	I:C1254351
intramuscular	B:C0442117
gene	O
transfer	I:C1517499
is	O
an	O
effective	O
treatment	O
for	O
moderate	O
to	O
severe	O
claudication	O
due	O
to	O
chronic	O
lower	O
limb	I:C0023216
ischemia	O
in	O
routine	O
clinical	O
practice	O
.	O

pl	O
-VEGF165	I:C1254351
intramuscular	O
gene	B:C1517499
transfer	I:C1517499
is	O
an	O
effective	O
treatment	O
for	O
moderate	O
to	O
severe	O
claudication	O
due	O
to	O
chronic	O
lower	O
limb	I:C0023216
ischemia	O
in	O
routine	O
clinical	O
practice	O
.	O

pl	O
-VEGF165	I:C1254351
intramuscular	O
gene	O
transfer	I:C1517499
is	O
an	O
effective	O
treatment	B:C0087111
for	O
moderate	O
to	O
severe	O
claudication	O
due	O
to	O
chronic	O
lower	O
limb	I:C0023216
ischemia	O
in	O
routine	O
clinical	O
practice	O
.	O

pl	O
-VEGF165	I:C1254351
intramuscular	O
gene	O
transfer	I:C1517499
is	O
an	O
effective	O
treatment	O
for	O
moderate	O
to	O
severe	O
claudication	B:C1456822
due	O
to	O
chronic	O
lower	O
limb	I:C0023216
ischemia	O
in	O
routine	O
clinical	O
practice	O
.	O

pl	O
-VEGF165	I:C1254351
intramuscular	O
gene	O
transfer	I:C1517499
is	O
an	O
effective	O
treatment	O
for	O
moderate	O
to	O
severe	O
claudication	O
due	O
to	O
chronic	O
lower	B:C0023216
limb	I:C0023216
ischemia	O
in	O
routine	O
clinical	O
practice	O
.	O

pl	O
-VEGF165	I:C1254351
intramuscular	O
gene	O
transfer	I:C1517499
is	O
an	O
effective	O
treatment	O
for	O
moderate	O
to	O
severe	O
claudication	O
due	O
to	O
chronic	O
lower	O
limb	I:C0023216
ischemia	B:C0022116
in	O
routine	O
clinical	O
practice	O
.	O

